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Summary
Colorectal cancer (CRC) is one of the most prevalent oncological diseases globally, taking 3rd place in incidence in the 
general population. High in mortality, it is also a form of cancer whose outcome is highly dependable on its stage at diag-
nosis. therefore, many countries have adopted a more or less successful screening process to ensure early diagnosis and, in 
turn, higher survival rates and better results overall. The COVID-19 pandemic has altered the established medical routines 
worldwide, with massively postponing diagnostic procedures and elective surgeries. This study aims to measure the effect 
the pandemic has had on colorectal cancer treatment in our institution. Variables such as deferral time from diagnosis to 
commencement of treatment, lapse of time between different phases of the treatment process, time of presentation (elective 
versus emergent surgery), the physical status of the patient at the time of surgery (ASA classification) and metastatic index 
(positive lymph node ratio), were taken into account. We juxtaposed data from patients treated at the Surgical Department 
of Clinical Hospital Center in Zagreb in 2019 and 2020, the latter being heavily affected by the pandemic. In 2019 and 2020, 
347 and 314 patients, respectively, with c18-c20 diagnoses (International Statistical Classification of Diseases and Related Health 
Problems ICD-10), have been treated at our Hospital. With exclusion criteria applied, the patient count falls to 173 for 2019 
and 157 for 2020. these numbers include operated cases with or without an anastomosis formation and with or without 
neoadjuvant chemotherapy applied. From the analysis we excluded patients with recurrent colorectal tumors, synchronous 
and metachronous tumors, and patients treated palliatively. Furthermore, colorectal adenomas were also excluded from the 
study. Our data shows significant difference between observed variables in the two patient groups, attributed to the COV-
iD-19 pandemic. since there is still no reliable way to predict the duration of this global health crisis, it is imperative to im-
plement strategies to lessen the damaging effect the pandemic has had on favourable oncosurgical treatment outcomes in 
colorectal cancer patients.
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INTRODUCTION
the coViD-19 pandemic was announced in 
March 2020, and it is safe to say that since then 
everyday life of health professionals and that of 
patients has changed drastically. Most of the re-
sources worldwide have been channelled towards 
combating the ever more challenging health crisis. 
screening programs and elective procedures have 
been put on the back burner, with numbers of 
medical staff simply unable to rise to the demands 
of the new disadvantageous situation. Many na-
tional studies have reported a significant decrease 
in diagnostic procedures and a halt in national 
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screening programmes for crc (1–6).  a addi-
tional issues of concern are the impact of coV-
iD-19 infection on the oncological patients (7), as 
availability and adequate use of personal protec-
tion equipment (8). The latter has an obvious ef-
fect on elective surgery and employment of mini-
mally invasive methods. one study showed a sig-
nificant increase in 30-day mortality in patients 
with a perioperative (7 days before surgery and 30 
days after surgery) sars-cov-2 infection. nearly 
half of these patients had postoperative pulmo-
nary complications with an overall mortality of 
23,5%, which was even higher in persons over 70 
years of age (9). gastrointestinal complications in 
critically ill coViD patients have also been ob-
served (10) which could alter the treatment out-
come in crc patients. our study aims to under-
stand the repercussions the pandemic has had on 
the oncosurgical treatment process for crc pa-
tients. this report is a single institution, tertiary 
centre experience from Croatia. Colorectal cancer 
seemed like the sensible choice since it has one of 
the highest incidences among cancers worldwide. 
When mortality in the general population is eval-
uated, it is second only to lung cancer, with a toll 
of over 900 000 lives annually (11–14). in the year 
2020, crc was the most frequently diagnosed 
cancer in croatia, with 3 706 new cases, similar to 
the prior years (15,16). Mirroring global trends, 
data from the croatian national cancer registry 
recognise it as the second most often identified 
cause of death in the Croatian population. With 
oncological patients being in the high-risk immu-
nosuppressed subgroup, the balance between the 
dangers of the infection and the steady advance-
ment of the malignant disease is fragile (17). inter-
national societies such as the american college of 
surgeons (acs), society for surgical oncology 
(sso), european society for Medical oncology 
(esMo), association of coloproctology of great 
Britain and ireland (acpgBi), have formed guide-
lines to facilitate decision making and triage pro-
cess (18–21). early on in the coViD-19 crisis, it 
was evident that losses regarding oncological care 
are to be expected. The absolute and final scope of 
Table 1
Patients with CRC (C18-C2O) treated at Clinical Hospital 
Centre Zagreb in 2019. versus 2020.
2019. 2020.
Total number of CRC patients 347 314
Exclusion criteria applied 173 157
Table 2.
Descriptive statistics by gender, age and surgical procedures
Year
2019 2020
N % N %
Gender
Male 96 55,5 98 62,4
Female 77 44,5 59 37,6
Min Max Median Std Dev Min Max Median Std Dev
Age 34 89 67 11,189 27 90 69 11,307
Surgical procedure N % N %
Left colectomy 9 5,2 6 3,8
Total colectomy 5 2,9 1 0,6
Hartmann procedure 23 13,3 34 21,7
Right hemicolectomy 46 26,6 52 33,1
Subtotal colectomy 2 1,2 1 0,6
Rectal resection 51 29,5 35 22,3
Sigmoid resection 19 11 12 7,6
Abdominoperineal excision 14 8,1 14 8,9
Trasnversal colon resection 3 1,7 2 1,4
Transanal excision 1 0,5 0 0
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the problem will significantly depend on the du-
ration of the pandemic.
MATERIALS AND METHODS
this study is a single institution, tertiary cen-
tre experience, from Croatia. The data were col-
lected retrospectively and included crc patients 
with icD-10 (International Statistical Classification 
of Diseases and Related Health Problems) diagnoses 
c18-c20, treated at the surgical Department of 
clinical Hospital centre Zagreb, comparing one-
year periods of 2019 and 2020. apart from the di-
agnoses mentioned above, inclusion criteria de-
manded that treatment was of curative surgical 
nature where tumour resection was performed 
(whether or not an anastomosis was constructed). 
The study also did not differentiate between pa-
tients who have received neoadjuvant oncological 
treatment from those who have not. Both elective-
ly operated and emergently treated patients were 
included. From the further analysis, we excluded 
patients with recurrent tumors, synchronous and 
metachronous tumors, patients treated palliative-
ly without curative intent, patients with the patho-
histological diagnosis of colorectal adenoma, and 
patients operated due to metastatic disease or late 
postoperative complications.
at our instituion we treated 347 patients with 
a diagnosis of CRC in 2019., and 314 in 2020. When 
exclusion criteria are applied, the figures fall to 
173 and 157, respectively. (table 1)
We analysed various parameters between the 
two groups. percentage of emergent operations 
from the total number of treated individuals, de-
ferral time from diagnosis to commencement of 
treatment, further detailed with a lapse of time be-
tween different phases of the treatment process, 
physical status of the patient at the time of surgery 
(ASA classification), TNM stage of cancer con-
firmed by pathohistology and finally the lymph 
node (LN) count as a metastatic index (positive 
lymph node ratio, lnr) as an important prognos-
tic factor in tnM stage 3 cancer (22–27).
Statistical analysis
all analyses were performed using spss for 
Windows version 25 (SPSS Inc, USA). The descrip-
tive statistic was used for the comparison of two 
groups by year. The difference between groups 
was assessed using the independent t-test proce-
dure for comparing mean values. Significance was 
determined by a probability value <0.05, with all p 
values two-sided.
RESULTS
in 2019. a total of 173 colorectal carcinoma 
patients were treated at our Institution (exclusion 
criteria applied). 96 (55,5%) of the individuals 
were men, and 77 (44,5%) were women. Median 
age for all patients was 67 years. the three most 
often performed operations were an anterior 
colorectal resection with a colorectal anastomosis 
Figure 1. Percentage of emergency colorectal cases per year.
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(29,5%), right hemicolectomie (26,6%) and Hart-
mann’s procedure with closure of the anorectal 
stump and formation of an end colostomy (13,3%). 
(table 2)
A total of 157 patients (exclusion criteria ap-
plied) were treated at our surgical Department in 
the year 2020, and of these patients, 98 (62,4%) 
were men, and 59 (35,6%) were women with an 
overall median age of 69 years. a right hemicolec-
tomie was performed in 33,1% of cases, an anteri-
or resection in 22,3% of patients and finally Hart-
mann’s procedure in 21,7%. (table 2)
When the data between 2019 and 2020 are 
compared, a rise in procedures done in an emer-
gent setting can be observed (15,3% versus 26,11%, 
respectively) (figure 1) with a decline in minimal-
ly invasive procedures. (figure 2)
The following variable we examined was the 
asa stage at the time of surgery as a universally 
accepted method of evaluating a patient’s health 
prior to surgery (28). Data show a significant de-
crease in the asa 2 subgroup in 2020 compared to 
2019, the asa 2 subgroup being patients where 
good treatment results are generally expected. 
Healthy individuals without comorbidities, treat-
ed for crc, iare scarce. (table 3)
the tumor, node, Metastasis (tnM) staging 
system was used as a parameter for late diagnosis 
with less favourable outcomes. our analysis used 
the four-grade system proposed by the american 
Joint Committee on Cancer (AJCC)/Union for In-
ternational cancer control (Uicc) (29). interest-
ingly enough, fewer histologically advanced tu-
mours (grade 3 and 4) were found in the year 2020 
compared to 2019 (55,1% versus 77,7%). it remains 
unclear whether this finding is attributed to the 
overall lower number of treated patients in 2020, 
with perhaps more operations in the emergent set-
ting be expected in the future. (Table 4)
Figure 2. Percentage of cases operated via minimally invasive procedure
Table 4








Distribution of ASA stages among operated patients  
(ASA 1 = patient without comorbidities; ASA 2 = a patient 
with mild systemic disease; ASA 3 = a patient with  
severe systemic disease; ASA 4 = a patient with severe  
systemic disease that is a constant threat to life;  
ASA 5= a moribund patient who is not expected to  
survive without the operation) (28)
Year 2019 2020
ASA 1 2 1
ASA 2 80 55
ASA 3 77 76
ASA 4 7 4
ASA 5 1 0




Deferral from the initial diagnosis to start of treatment and lapse of time between different stages  
of the oncosurgical treatment process
Year N Mean (Days) Std. Deviation Sig.
Colonoscopy to Surgery 2019 91 40,4725 36,70160
,115
2020 65 45,1846 74,70649
Surgeon referral to Surgery 2019 135 24,3111 32,83574
,005
2020 96 32,0000 63,16645
Surgery to Oncologist referral 2019 128 35,4766 20,99567
,004
2020 122 44,6311 28,43877
Surgery to Chemotherapy 2019 70 59,0286 26,64200
,005
2020 81 76,4321 41,78724
Deferral from the initial diagnosis to the be-
ginning of treatment was measured in days and 
compared between the two groups. We noticed a 
prolonged time between different stages of surgi-
cal and oncological treatments, a statistically sig-
nificant difference was observed at data points 
from surgeon referral to surgery, from surgery to 
oncologist referral and from surgery to chemo-
therapy initiation. (table 5)
The final variable measured was lymph node 
count (LN), the positivity of examined LNs to tu-
mour cells (pLN), and Metastatic Index (positive 
lymph nodes ratio, lnr). it is a standing surgical 
practice to target having at least 12 mesenteric 
lymph nodes in the resected colorectal tumour 
specimen. in the group of patients from 2019, the 
mean number of examined LNs per patient was 
17.28 (n=172, std. Dev. = 8.409), while in 2020, it 
was 16.57 (n=157, std. Dev. = 6.264) (figure 3). 
studies show that lymph node count is an impor-
tant prognostic factor for overall survival in crc, 
especially in more advanced disease such as tnM 
stage III (23,24,30–32). Lately, the Metastatic Index 
has been more frequently used as it represents the 
ratio between metastatic lymph nodes and the to-
tal number of dissected lymph nodes (30–32). 
ranging in value from 0 to 100% predicts a less 
optimal outcome the closer to 100% it falls. the 
mean value of lnr in 2019 was 10.2983, while it 
was 7.9658 in 2020. (table 6)
Figure 3. The blue line depicts the number of examined lymph 
nodes per patient through 2019/2020. The number of positive 
lymph nodes is marked with the red line.
Table 6.
Group Statistics
Year N Mean Std. Deviation Std. Error Mean
Lymph nodes ratio  
(LNR)
2020 157 7,9658 15,79241 1,26037
2019 172 10,2983 19,68752 1,50116
Examined lymph nodes  
(LN)
2020 157 16,57 6,264 ,500
2019 172 17,28 8,409 ,641
Positive lymph nodes  
(pLN)
2020 157 1,36 2,658 ,212




Many factors influence the outcome of colo-
rectal cancer treatment. It has long been known 
that CRC screening has excellent value in dimin-
ishing mortality rates of this malignancy. precan-
cerous lesions of the colon are well defined, and 
higher histological cancer stages upon initial diag-
nosis have a detrimental effect on the 5-year sur-
vival rate (16,26,33). Many national reports reveal 
significant declines in CRC screening during CO-
ViD times (34,35), with some of them proposition-
ing to alter the standardised screening process, 
making it more attainable in pandemic times 
(36,37). the crc screening program in croatia 
started in 2008 and has since then been a valuable 
asset to national health (16,38).
The differences in total numbers of CRC pa-
tients registered at our institution (347 in 2019 ver-
sus 314 in 2020) can at least partially be attributed 
to the postponement of routine diagnostics. one 
study investigated crc treatment outcomes in 
younger individuals that were not included in the 
screening process. on average, these patients pre-
sented with more advanced disease and poorly 
differentiated histology (higher TNM grade) (39). 
one could argue that early-onset crc has a more 
aggressive clinical presentation. But when histo-
logical stages were compared, the younger pa-
tients had better outcomes than older individuals 
troubled with comorbidities. the contrast can 
therefore be fairly attributed to failure of early rec-
ognition of the disease. to assume that one could 
entirely mitigate the current and future effect of 
coViD-19 on routine diagnostic and oncological 
services is not realistic. societies, such as the 
american college of surgeons (acs), society for 
surgical oncology (sso), european society for 
Medical oncology (esMo), association of colo-
proctology of great Britain and ireland (acpgBi), 
have formed guidelines to facilitate the decision 
making and triage process and thereby alleviate 
the burden the pandemic has put on oncological 
shoulders (18,20,21,40). the esMo guidelines 
propose a priority ranking where patients with 
signs of mechanical obstruction, bowel perfora-
tion and postoperative complications take prece-
dence, while diagnostic endoscopy and radiologi-
cal staging are considered a medium priority. re-
staging without the intent of curative surgery 
stands lowest in priority (18).
esMo guidelines suggest considering short-
course neoadjuvant chemotherapy with a possible 
watch and wait approach in patients with a complete 
response (18). The latter recommendations are sup-
ported by many studies which have investigated 
the relations between neoadjuvant chemotherapy 
(short- and long-course) and timing of surgery. 
they mostly found that delay to surgery of 4 to 8 
weeks (56 to 60 days being the cut-off in some stud-
ies) is safe and feasible, while a too-short interval 
between neoadjuvant chemotherapy and surgery 
(1 week and less) can even have detrimental effects 
on the final outcomes (25,41–45).
In conclusion, the ramifications COVID-19 
pandemic has had on crc patients at our institu-
tion are evident. With fewer total cases discov-
ered, more advanced disease is expected in the 
future. patients were more frequently of poorer 
physical status at the time of operation, which is a 
negative outcome predictor. the drop in minimal-
ly invasive surgery is partially owned to dimin-
ished hospital and equipment capacities, and con-
sequences of prolonged deferral between onco-
surgical treatment phases are yet to be established. 
from the presented results, a prolongation of cru-
cial stages for treating crc patients in 2020 is vis-
ible. proportion of tnM stage iii patients, with a 
better metastatic index, increased in 2020, while 
the waiting time for chemotherapy, from which 
this subgroup of patients would benefit the most, 
was extended, which is particularly striking. Try-
ing at the moment to implement the latest recom-
mendations of relevant institutions concerning 
crc treatment and diagnosis, new data gathering 
will be needed to estimate if COVID-19 effects 
have been successfully minimised.
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COVID-19 I KOLOREKTALNI KARCINOM – TOKSIČNE POVEZNICE I KAKO IH PREKINUTI:  
KBc ZagreB, isKUstVo terciJarnog centra
P. Matošević, V. Biošić, L. Brkić, A. Matijević, O. Miličević, I. Trkulja, H. Silovski i E. Kinda
Kolorektalni karcinom jedna je od najčešćih onkoloških bolesti u svijetu. Uz visoki mortalitet obilježena je i ovisnošću 
ishoda liječenja o stadiju bolesti u trenutku dijagnoze. Mnoge su države stoga usvojile više ili manje uspješne programe 
probira kako bi osigurale ranu dijagnozu, bolje stope preživljenja te generalno optimalnije ishode liječenja. Pandemija 
 COVID-19 u kratkom je roku promijenila temelje medicinske svakodnevice uz nemale odgode dijagnostičkih procedura i 
elektivnih zahvata. Cilj ovog rada jest procijeniti utjecaj koji je pandemija imala na liječenje kolorektalnog karcinoma u našoj 
ustanovi. Uspoređivana su dva jednogodišnja razdoblja – 2019. i 2020. od kojih je potonja godina bila značajno pogođena 
COVID-19 pandemijom. Uspoređivali smo podatke pacijenta liječenih na Zavodu za Kirurgiju Kliničkog bolničkog Centra 
Zagreb, vođenih pod MKB dijagnozama C18-C20. U 2019. godini na našem je Zavodu liječeno 347 pacijena s kolorektalnim 
karcinom, po primjeni kriterija isključenja ta brojka pada na 173. Bolesnika s operiranim karcinomom koloektuma u 2020. 
godini u našoj je ustanovi bilo 314, po primjeni kriterija isključenja 157. Praćeni parametri uključivali su vremensku odgodu 
od incijalne dijagnoze do početka liječenja, vrijeme proteklo između različitih etapa onko-kirurškog liječenja, odnos elektiv-
nih i hitnih zahvata, fizičku spremnost pacijenata u vrijeme operacije (ASA klasifikacija) te metastatski index (udio pozitiv-
nih metastatskih limfnih čvorova u dobivenim preparatima). U studiju su uključeni bolesnici neovisno o primjeni neoadju-
vantne kemoterapije te neovisno je li intraoepracijski uspostavljen kontinuitet probavne cijevi. Recidivni tumori, metakroni 
i sinkroni tumori, palijativno liječeni pacijenti, reoperirani te pacijenti operirani uslijed kolorektalnog adenoma nisu uklju-
čeni u ovu studiju. Naši podaci pokazuju značajne razlike među praćenim parametrima u dva razdoblja te se iste uvelike 
pripisuju utjecaju COVID-19 pandemije. Kako su budućnost i trajanje ove medicinske krize još uvijek neizvjesni, potrebno 
je što prije usvojiti strategije kojima bi se smanjio razorni utjecaj pandemije na ishode liječenja bolesnika sa kolorektalnim 
karcinomom.
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